Proactive Investors - Run By Investors For Investors

Summit Therapeutics shows off potential of Discuva platform at Berlin conference

The presentations are being made at Novel Antimicrobials and AMR Diagnostics 2019, which is being held in Berlin today and tomorrow
bacteria
Many infectious diseases are becoming resistant to current antibiotic treatments

Summit Therapeutics PLC (LON:SUMM) has unveiled two new presentations at an industry conference in Berlin.

The presentations show off the potential of Summit’s Discuva platform, which it is using to identify and develop new antibiotics that infections such as gonorrhoea and staph aren’t resistant to.

READ: Summit’s gonorrhoea antibiotic showing promise

Several programmes of new mechanism antibiotics have emerged from the Discuva Platform, including one targeting gonorrhoea and another targeting ESKAPE pathogens.

Both of those programmes are being discussed at the conference.

“Antimicrobial resistance is a worldwide problem. We need to see scientific innovation to prevent an era of untreatable infections,” said Summit’s president of R&D, David Roblin.

“Through the Discuva Platform, we are using novel science to create targeted, new mechanism antibiotics that are optimised against resistance development.

“Our goal is to develop the most appropriate drug for a specific patient, thereby improving patient outcomes and giving physicians options to address the spread of AMR.”

Summit shares were up 1.6% to 30.5p in early afternoon trading on Thursday.

View full SUMM profile View Profile

Summit Therapeutics PLC Timeline

Related Articles

1550762209_shutterstock_291998651.jpg
February 21 2019
Motif’s lead drug candidate is iclaprim, a next-generation antibiotic for which it was seeking US FDA approval for use in patients with acute bacterial skin and skin structure infections
Cyrptocurrencies
June 27 2018
Lancor Scientific is aiming to carry out an initial coin offering by issuing Medici, a new currency based on Ethereum to help Tumour Trace to fund further development
blood
December 03 2018
Feraccru already has EU approval while in Switzerland the drug can be used for iron deficiency anaemia in adults with inflammatory bowel disease

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use